Q3 EPS Forecast for Alnylam Pharmaceuticals Cut by Analyst

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) – Equities researchers at HC Wainwright decreased their Q3 2026 earnings per share (EPS) estimates for Alnylam Pharmaceuticals in a note issued to investors on Tuesday, August 4th. HC Wainwright analyst P. Trucchio now forecasts that the biopharmaceutical company will earn $1.65 per share for the quarter, down from their prior estimate of $1.79. HC Wainwright has a “Buy” rating and a $455.00 price target on the stock. The consensus estimate for Alnylam Pharmaceuticals’ current full-year earnings is $6.60 per share. HC Wainwright also issued estimates for Alnylam Pharmaceuticals’ Q4 2026 earnings at $1.97 EPS, FY2026 earnings at $6.30 EPS, FY2027 earnings at $9.50 EPS, FY2028 earnings at $10.55 EPS, FY2029 earnings at $14.88 EPS and FY2030 earnings at $19.42 EPS.

Several other brokerages have also commented on ALNY. Morgan Stanley decreased their price target on Alnylam Pharmaceuticals from $400.00 to $300.00 and set an “equal weight” rating on the stock in a research note on Friday, July 31st. JPMorgan Chase & Co. cut their price objective on Alnylam Pharmaceuticals from $400.00 to $375.00 and set an “overweight” rating for the company in a research report on Friday, July 31st. Stifel Nicolaus reduced their price objective on shares of Alnylam Pharmaceuticals from $444.00 to $318.00 and set a “buy” rating on the stock in a report on Friday, July 31st. Wells Fargo & Company decreased their target price on shares of Alnylam Pharmaceuticals from $377.00 to $316.00 and set an “equal weight” rating on the stock in a research report on Friday, July 31st. Finally, Raymond James Financial raised shares of Alnylam Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a $420.00 target price for the company in a research note on Monday. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $396.72.

Alnylam Pharmaceuticals Price Performance

ALNY stock opened at $216.12 on Friday. Alnylam Pharmaceuticals has a 52-week low of $197.81 and a 52-week high of $495.55. The company has a quick ratio of 3.06, a current ratio of 3.05 and a debt-to-equity ratio of 0.75. The stock has a market cap of $28.92 billion, a price-to-earnings ratio of 40.17 and a beta of 0.30. The business has a fifty day moving average of $281.78 and a two-hundred day moving average of $306.88.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of ALNY. J.Safra Asset Management Corp acquired a new position in Alnylam Pharmaceuticals in the 2nd quarter valued at about $940,000. Flputnam Investment Management Co. acquired a new stake in shares of Alnylam Pharmaceuticals during the second quarter worth about $831,000. Global Retirement Partners LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the second quarter worth about $570,000. SCS Capital Management LLC purchased a new position in shares of Alnylam Pharmaceuticals in the second quarter valued at approximately $34,784,000. Finally, Bank of New York Mellon Corp purchased a new position in shares of Alnylam Pharmaceuticals in the second quarter valued at approximately $148,128,000. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, Director David E. I. Pyott sold 3,830 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, June 1st. The stock was sold at an average price of $299.18, for a total value of $1,145,859.40. Following the completion of the sale, the director directly owned 1,582 shares of the company’s stock, valued at approximately $473,302.76. The trade was a 70.77% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.86% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.